Keywords
Last Name
Institution

ZEEV ESTROV

TitleProfessor
InstitutionMD Anderson
DepartmentLeukemia
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 Mar 24. PMID: 28338082.
      View in: PubMed
    2. Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 Feb; 31(2):318-324. PMID: 27795561.
      View in: PubMed
    3. Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, Knez L, Bozinovic K, Harris DM, Spaeth EL, Post SM, Multani AS, Rampal RK, Ahn J, Levine RL, Creighton CJ, Kantarjian HM, Estrov Z. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016 Aug 22; 213(9):1723-40. PMID: 27481130; PMCID: PMC4995084 [Available on 02/22/17].
    4. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400. PMID: 26492205; PMCID: PMC4826052 [Available on 02/01/17].
    5. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-55. PMID: 26432046.
      View in: PubMed
    6. Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma. 2016 Jan; 57(1):237-9. PMID: 25904378.
      View in: PubMed
    7. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 1; 121(23):4158-64. PMID: 26308885.
      View in: PubMed
    8. Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. Am J Hematol. 2015 Aug; 90(8):752-3. PMID: 25850565.
      View in: PubMed
    9. Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer. 2015 Nov 1; 121(21):3869-76. PMID: 26218678.
      View in: PubMed
    10. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015 Oct 15; 121(20):3612-21. PMID: 26193999.
      View in: PubMed
    11. Ohanian M, Bueso-Ramos C, Ok CY, Lin P, Patel K, Alattar ML, Khoury JD, Rozovski U, Estrov Z, Huh YO, Cortes J, Abruzzo LV. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet. 2015 Nov; 208(11):571-4. PMID: 26382622.
      View in: PubMed
    12. Masarova L, Newberry KJ, Pierce SA, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res. 2015 Aug; 39(8):822-7. PMID: 26012362.
      View in: PubMed
    13. Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D'Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps TJ, Kay NE, Keating M, Calin GA. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine. 2015 Jun; 2(6):572-82. PMID: 26288818.
      View in: PubMed
    14. Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, Fayad L, Pemmaraju N. Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. Am J Hematol. 2015 Nov; 90(11):1091-2. PMID: 25808231.
      View in: PubMed
    15. Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol. 2015 May 10; 33(14):1557-63. PMID: 25847930.
      View in: PubMed
    16. Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien S. High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol. 2015 Jun; 90(6):471-7. PMID: 25683856.
      View in: PubMed
    17. Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res. 2015 May; 13(5):944-53. PMID: 25733697.
      View in: PubMed
    18. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015 Apr; 90(4):276-81. PMID: 25530214.
      View in: PubMed
    19. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26; 125(13):2062-7. PMID: 25573991.
      View in: PubMed
    20. Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov Z. Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol. 2015 May; 169(4):595-7. PMID: 25413673.
      View in: PubMed
    21. Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, Wang X, Burger J, Ferrajoli A, Kantarjian H, O'Brien S, Wierda W, Estrov Z, Keating M. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015 Jun; 56(6):1643-50. PMID: 25308294.
      View in: PubMed
    22. Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4. PMID: 25368968.
      View in: PubMed
    23. Rozovski U, Ohanian M, Ravandi F, Garcia-Manero G, Faderl S, Pierce S, Cortes J, Estrov Z. Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leuk Lymphoma. 2015 May; 56(5):1392-7. PMID: 25110819.
      View in: PubMed
    24. Li J, Kurasawa Y, Wang Y, Clise-Dwyer K, Klumpp SA, Liang H, Tailor RC, Raymond AC, Estrov Z, Brandt SJ, Davis RE, Zweidler-McKay P, Amin HM, Nagarajan L. Requirement for ssbp2 in hematopoietic stem cell maintenance and stress response. J Immunol. 2014 Nov 1; 193(9):4654-62. PMID: 25238756.
      View in: PubMed
    25. Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res. 2014 Oct; 38(10):1212-6. PMID: 25217891; PMCID: PMC4182146.
    26. Chen Y, Estrov Z, Pierce S, Qiao W, Borthakur G, Ravandi F, Kadia T, Brandt M, O'Brien S, Jabbour E, Garcia-Manero G, Cortes J, Beran M. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma. 2015 Apr; 56(4):1012-9. PMID: 25048874.
      View in: PubMed
    27. Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 2014 Nov 15; 120(22):3494-501. PMID: 25043749.
      View in: PubMed
    28. Ohanian M, Huang RS, Yakoushina TV, Estrov Z, Juneja H, Chen L, Idowu M, Abruzzo LV. Isolated mesenteric CD20-positive myeloid sarcoma. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):e217-20. PMID: 25131853.
      View in: PubMed
    29. Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O'Brien S, Faderl S, Keating M, Estrov Z. STAT3-activated GM-CSFR? translocates to the nucleus and protects CLL cells from apoptosis. Mol Cancer Res. 2014 Sep; 12(9):1267-82. PMID: 24836891.
      View in: PubMed
    30. Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10. PMID: 24875590.
      View in: PubMed
    31. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3797-802. PMID: 24778152; PMCID: PMC4055926.
    32. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9. PMID: 24737502.
      View in: PubMed
    33. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014 Jun 12; 123(24):3727-32. PMID: 24705492; PMCID: PMC4067501.
    34. Rozovski U, Li P, Harris D, Ohanian M, Kantarjian H, Estrov Z. Interleukin-7 receptor-? gene mutations are not detected in adult T-cell acute lymphoblastic leukemia. Cancer Med. 2014 Jun; 3(3):550-4. PMID: 24678068.
      View in: PubMed
    35. Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith SC, Jain N, Estrov Z, O'Brien S, Wierda WG, Lerner S, Ferrajoli A. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014 May 1; 123(18):2783-90. PMID: 24615780; PMCID: PMC4123418.
    36. Chae YK, Trinh L, Jain P, Wang X, Rozovski U, Wierda WG, Keating MJ, Estrov Z. Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 Feb 27; 123(9):1424-6. PMID: 24578497; PMCID: PMC3938153.
    37. Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5. PMID: 24487412; PMCID: PMC4091714.
    38. Strati P, Manning JT, Ok CY, Garcia-Manero G, Estrov Z. Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Jun; 55(6):1425-7. PMID: 23987820.
      View in: PubMed
    39. Jain P, Baez-Vallecillo L, Huh YO, Benjamini O, Abruzzo L, O'Brien S, Pemmaraju N, Keating M, Gagel RF, Estrov Z. Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile. Leuk Lymphoma. 2014 Apr; 55(4):944-6. PMID: 23829280; PMCID: PMC4102379.
    40. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One. 2013; 8(12):e83830. PMID: 24376763.
      View in: PubMed
    41. Quintás-Cardama A, Grgurevic S, Rozovski U, Li P, Estrov Z, Cortes J. Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):681-5. PMID: 24060288.
      View in: PubMed
    42. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ?60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6. PMID: 23877926; PMCID: PMC4110914.
    43. Rozovski U, Keating MJ, Estrov Z. Targeting inflammatory pathways in chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2013 Dec; 88(3):655-66. PMID: 23941728.
      View in: PubMed
    44. Irwin ME, Nelson LD, Santiago-O'Farrill JM, Knouse PD, Miller CP, Palla SL, Siwak DR, Mills GB, Estrov Z, Li S, Kornblau SM, Hughes DP, Chandra J. Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. PLoS One. 2013; 8(8):e70608. PMID: 23936456; PMCID: PMC3731286.
    45. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7. PMID: 23760779; PMCID: PMC3923606.
    46. Rozovski U, Hazan-Halevy I, Keating MJ, Estrov Z. Personalized medicine in CLL: current status and future perspectives. Cancer Lett. 2014 Sep 28; 352(1):4-14. PMID: 23879961.
      View in: PubMed
    47. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21. PMID: 23836561.
      View in: PubMed
    48. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013 Sep 12; 122(11):1891-9. PMID: 23821659; PMCID: PMC3779381.
    49. Benjamini O, Jain P, Konoplev SN, Yin CC, Abruzzo L, Wotherspoon AC, Dearden C, Shpall EJ, Estrov Z, Keating MJ. CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemma. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):610-3. PMID: 23800602; PMCID: PMC4167023.
    50. Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon ?-2a. Blood. 2013 Aug 8; 122(6):893-901. PMID: 23782935; PMCID: PMC3739035.
    51. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3. PMID: 23774633.
      View in: PubMed
    52. Li P, Grgurevic S, Liu Z, Harris D, Rozovski U, Calin GA, Keating MJ, Estrov Z. Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia. PLoS One. 2013; 8(6):e64678. PMID: 23750211; PMCID: PMC3672147.
    53. Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53. PMID: 23733767; PMCID: PMC4878053.
    54. Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien S, Wierda WG, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer. 2013; 12:50. PMID: 23725032.
      View in: PubMed
    55. Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep; 22(5):605-11. PMID: 23701251; PMCID: PMC3745781.
    56. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-66. PMID: 23530930; PMCID: PMC4068703.
    57. Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9. PMID: 23512829.
      View in: PubMed
    58. Jain P, Benjamini O, Konoplev S, Mohamed MS, Romo CG, Estrov Z. Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein-Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Nov; 54(11):2540-2. PMID: 23387894.
      View in: PubMed
    59. Jain P, Benjamini O, Pei L, Caraway NP, Landon G, Kim S, Shivaprasad S, Woodman K, O'Brien S, Ferrajoli A, Kadia T, Estrov Z. Central nervous system Richter's transformation and parvovirus B19 infection. Leuk Lymphoma. 2013 Sep; 54(9):2070-2. PMID: 23320889; PMCID: PMC4114215.
    60. Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013 Nov; 54(11):2537-9. PMID: 23343175.
      View in: PubMed
    61. Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, Estrov Z. Is acute myeloid leukemia a liquid tumor? Int J Cancer. 2013 Aug 1; 133(3):534-43. PMID: 23280377; PMCID: PMC3904286.
    62. Benjamini O, Jain P, Schlette E, Sciffman JS, Estrov Z, Keating M. Chronic lymphocytic leukemia with central nervous system involvement: a high-risk disease? Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):338-41. PMID: 23332395.
      View in: PubMed
    63. Rozovski U, Keating M, Estrov Z. The significance of spliceosome mutations in chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Jul; 54(7):1364-6. PMID: 23270583.
      View in: PubMed
    64. Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, Bickel S, Keating MJ, Estrov Z. Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):292-5. PMID: 23265768.
      View in: PubMed
    65. Bhamidipati PK, Jabbour E, Konoplev S, Estrov Z, Cortes J, Daver N. Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):342-6. PMID: 23246163; PMCID: PMC4019340.
    66. Lamothe B, Lai Y, Hur L, Orozco NM, Wang J, Campos AD, Xie M, Schneider MD, Lockworth CR, Jakacky J, Tran D, Ho M, Dawud S, Dong C, Lin HK, Hu P, Estrov Z, Bueso-Ramos CE, Darnay BG. Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice. PLoS One. 2012; 7(12):e51228. PMID: 23251462; PMCID: PMC3519594.
    67. Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42. PMID: 23135353; PMCID: PMC4181539.
    68. Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek S. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood. 2012 Sep 27; 120(13):2768-9. PMID: 23019204; PMCID: PMC4081400.
    69. Ohanian M, Borthakur G, Quintas-Cardama A, Mathisen M, Cortés JE, Estrov Z, Pemmaraju N. Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):93-6. PMID: 23017332; PMCID: PMC4151170.
    70. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Sep 6; 489(7414):155-9. PMID: 22820254; PMCID: PMC3991463.
    71. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 9; 120(6):1202-9. PMID: 22718840.
      View in: PubMed
    72. Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31. PMID: 22665218; PMCID: PMC3981542.
    73. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):197-200. PMID: 22578814.
      View in: PubMed
    74. Chen Y, Kantarjian H, Estrov Z, Faderl S, Ravandi F, Rey K, Cortes J, Borthakur G. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):341-4. PMID: 22579233; PMCID: PMC4103411.
    75. Quintás-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep; 36(9):1124-7. PMID: 22475363; PMCID: PMC4152772.
    76. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8. PMID: 22422826; PMCID: PMC4081383.
    77. Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi F. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma. 2012 Sep; 53(9):1839-41. PMID: 22303899; PMCID: PMC4120044.
    78. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20. PMID: 22360602; PMCID: PMC3924750.
    79. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012 Jan; 87(1):127-9. PMID: 22072492.
      View in: PubMed
    80. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011 Oct 27; 118(17):4690-3. PMID: 21868570; PMCID: PMC4081364.
    81. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 1; 118(3):722-8. PMID: 21751197; PMCID: PMC4180241.
    82. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011 Aug 25; 118(8):2062-8. PMID: 21750315.
      View in: PubMed
    83. Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol. 2011 Dec; 42(12):1989-2000. PMID: 21733558.
      View in: PubMed
    84. Harris DM, Hazan-Haley I, Coombes K, Bueso-Ramos C, Liu J, Liu Z, Li P, Ravoori M, Abruzzo L, Han L, Singh S, Sun M, Kundra V, Kurzrock R, Estrov Z. Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells. PLoS One. 2011; 6(6):e21250. PMID: 21731684; PMCID: PMC3120836.
    85. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13. PMID: 21555694.
      View in: PubMed
    86. Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011 Jun 1; 71(11):3831-40. PMID: 21512135; PMCID: PMC4067142.
    87. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 1; 117(21):4869-77. PMID: 21480207; PMCID: PMC4160798.
    88. Liu Z, Hazan-Halevy I, Harris DM, Li P, Ferrajoli A, Faderl S, Keating MJ, Estrov Z. STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells. Mol Cancer Res. 2011 Apr; 9(4):507-15. PMID: 21364020; PMCID: PMC4212696.
    89. Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 2011 Sep 1; 117(17):3999-4008. PMID: 21858802; PMCID: PMC4349201.
    90. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44. PMID: 20960519; PMCID: PMC4061136.
    91. Ma W, Kantarjian H, Zhang X, Wang X, Estrov Z, O'Brien S, Albitar M. Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance. Leuk Res. 2011 Apr; 35(4):526-33. PMID: 20951430.
      View in: PubMed
    92. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27. PMID: 20843246.
      View in: PubMed
    93. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics. 2010 Aug 16; 5(6):499-508. PMID: 20484983; PMCID: PMC3322493.
    94. Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood. 2010 Nov 18; 116(20):4251-61. PMID: 20679526; PMCID: PMC4081283.
    95. Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One. 2010; 5(7):e11859. PMID: 20686606.
      View in: PubMed
    96. Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs. 2011 Dec; 29(6):1206-12. PMID: 20533075; PMCID: PMC4230707.
    97. Faderl S, Bueso-Ramos C, Liu Z, Pal A, Bornmann W, Ciurea DV, Harris D, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs. 2011 Oct; 29(5):1094-7. PMID: 20517635; PMCID: PMC4251765.
    98. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010 Jun 1; 116(11):2673-81. PMID: 20499401; PMCID: PMC4216809.
    99. Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z, Plunkett W. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood. 2010 Sep 9; 116(10):1737-46. PMID: 20479284; PMCID: PMC2947394.
    100. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 1; 28(16):2755-60. PMID: 20421540; PMCID: PMC4872315.
    101. Quintás-Cardama A, Manshouri T, Estrov Z, Harris D, Zhang Y, Gaikwad A, Kantarjian HM, Verstovsek S. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs. 2011 Oct; 29(5):818-26. PMID: 20372971; PMCID: PMC4170651.
    102. Bruey JM, Kantarjian H, Ma W, Estrov Z, Yeh C, Donahue A, Sanders H, O'Brien S, Keating M, Albitar M. Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res. 2010 Oct; 34(10):1320-4. PMID: 20362333; PMCID: PMC4108997.
    103. Wang Y, Klumpp S, Amin HM, Liang H, Li J, Estrov Z, Zweidler-McKay P, Brandt SJ, Agulnick A, Nagarajan L. SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability. Oncogene. 2010 May 27; 29(21):3044-53. PMID: 20348955; PMCID: PMC2878399.
    104. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62. PMID: 20212254; PMCID: PMC2930809.
    105. Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, Shanker S, Ferrajoli A, Keating MJ, Estrov Z. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood. 2010 Apr 8; 115(14):2852-63. PMID: 20154216; PMCID: PMC2918366.
    106. Estrov Z. The leukemia stem cell. Cancer Treat Res. 2010; 145:1-17. PMID: 20306242.
      View in: PubMed
    107. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6. PMID: 20008298.
      View in: PubMed
    108. Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10; 27(32):5418-24. PMID: 19826111.
      View in: PubMed
    109. Yeh CH, Tseng R, Hannah A, Estrov Z, Estey E, Kantarjian H, Albitar M. Clinical correlation of circulating heat shock protein 70 in acute leukemia. Leuk Res. 2010 May; 34(5):605-9. PMID: 19800118; PMCID: PMC4127889.
    110. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50. PMID: 19762485; PMCID: PMC4081374.
    111. Garg RJ, Kantarjian H, O'Brien S, Quintás-Cardama A, Faderl S, Estrov Z, Cortes J. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009 Nov 12; 114(20):4361-8. PMID: 19729517.
      View in: PubMed
    112. Sever M, Kantarjian H, Pierce S, Jain N, Estrov Z, Cortes J, Verstovsek S. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol. 2009 Nov; 90(4):522-5. PMID: 19728024; PMCID: PMC4209590.
    113. Bruey JM, Kantarjian H, Estrov Z, Zhang Z, Ma W, Albitar F, Abdool A, Thomas D, Yeh C, O'Brien S, Albitar M. Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia. Leuk Res. 2010 Feb; 34(2):173-6. PMID: 19679351; PMCID: PMC4132892.
    114. Carter BZ, Mak DH, Woessner R, Gross S, Schober WD, Estrov Z, Kantarjian H, Andreeff M. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009 Oct; 23(10):1755-62. PMID: 19458629.
      View in: PubMed
    115. Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar M. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009 Jun 1; 15(11):3820-6. PMID: 19458051.
      View in: PubMed
    116. Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009; 2:20. PMID: 19439093.
      View in: PubMed
    117. Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Res. 2009 May 1; 69(9):3910-7. PMID: 19383925; PMCID: PMC4220548.
    118. Vega-Ruiz A, Faderl S, Estrov Z, Pierce S, Cortes J, Kantarjian H, Ravandi F. Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol. 2009 May; 89(4):489-96. PMID: 19340529; PMCID: PMC4199302.
    119. Estrov Z. Stem cells and somatic cells: reprogramming and plasticity. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S319-28. PMID: 19778860.
      View in: PubMed
    120. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 1; 27(4):504-10. PMID: 19075265; PMCID: PMC4881307.
    121. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008 Oct 15; 113(8):2090-6. PMID: 18756533.
      View in: PubMed
    122. Yeh CH, Tseng R, Zhang Z, Cortes J, O'Brien S, Giles F, Hannah A, Estrov Z, Keating M, Kantarjian H, Albitar M. Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res. 2009 Feb; 33(2):212-7. PMID: 18715642; PMCID: PMC4163801.
    123. Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles F. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer. 2008 Jul 15; 113(2):360-6. PMID: 18473351.
      View in: PubMed
    124. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 1; 112(5):1638-45. PMID: 18565853; PMCID: PMC4081352.
    125. Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun; 99(6):1265-73. PMID: 18482053; PMCID: PMC4829954.
    126. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008 Aug 15; 112(4):981-9. PMID: 18495956; PMCID: PMC4081529.
    127. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008 May 1; 68(9):3413-20. PMID: 18451169; PMCID: PMC4096127.
    128. Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, Ferrajoli A, Keating M, Giles F, Albitar M. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer. 2008 Mar 15; 112(6):1306-12. PMID: 18224667.
      View in: PubMed
    129. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008 Jun 1; 111(11):5291-7. PMID: 18334676.
      View in: PubMed
    130. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008 Mar; 7(3):464-73. PMID: 18347134.
      View in: PubMed
    131. Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 1; 14(3):788-96. PMID: 18245540.
      View in: PubMed
    132. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008 Feb 6; 100(3):184-98. PMID: 18230792.
      View in: PubMed
    133. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203. PMID: 18182662.
      View in: PubMed
    134. Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2009 Feb; 31(1):97-105. PMID: 18190591; PMCID: PMC4163781.
    135. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 2007 Dec 1; 67(23):11291-9. PMID: 18056455.
      View in: PubMed
    136. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic acute leukaemia: a case series. Br J Haematol. 2007 Jul; 138(2):213-6. PMID: 17593028.
      View in: PubMed
    137. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007 Oct 1; 110(7):2302-8. PMID: 17596541.
      View in: PubMed
    138. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M, Jackson CE, Chen W, Estey E, Appelbaum FR. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood. 2007 Apr 1; 109(7):2999-3006. PMID: 17158228; PMCID: PMC1852228.
    139. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007 Jan 15; 109(2):248-55. PMID: 17154172.
      View in: PubMed
    140. Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood. 2007 Apr 15; 109(8):3470-8. PMID: 17202319.
      View in: PubMed
    141. Kornblau SM, Qiu YH, Bekele BN, Cade JS, Zhou X, Harris D, Jackson CE, Estrov Z, Andreeff M. Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells". Cell Cycle. 2006 Dec; 5(23):2769-77. PMID: 17172852.
      View in: PubMed
    142. Ferrajoli A, Faderl S, Ravandi F, Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets. 2006 Dec; 6(8):671-9. PMID: 17168672.
      View in: PubMed
    143. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006 Nov; 10(5):375-88. PMID: 17097560.
      View in: PubMed
    144. Montero AJ, Estrov Z, Freireich EJ, Khouri IF, Koller CA, Kurzrock R. Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma. 2006 Oct; 47(10):2049-54. PMID: 17071475.
      View in: PubMed
    145. Körbling M, Reuben JM, Gao H, Lee BN, Harris DM, Cogdell D, Giralt SA, Khouri IF, Saliba RM, Champlin RE, Zhang W, Estrov Z. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion. 2006 Oct; 46(10):1795-802. PMID: 17002637.
      View in: PubMed
    146. Lev EI, Estrov Z, Aboulfatova K, Harris D, Granada JF, Alviar C, Kleiman NS, Dong JF. Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix. Thromb Haemost. 2006 Oct; 96(4):498-504. PMID: 17003929.
      View in: PubMed
    147. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 1; 109(1):52-7. PMID: 16882708.
      View in: PubMed
    148. Kurzrock R, Talpaz M, Li L, Estrov Z. Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. Leuk Lymphoma. 2006 Aug; 47(8):1651-64. PMID: 16966279.
      View in: PubMed
    149. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9. PMID: 16882711; PMCID: PMC1895437.
    150. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res. 2007 Jan; 31(1):91-5. PMID: 16828865.
      View in: PubMed
    151. Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 2006 Apr 1; 66(7):3737-46. PMID: 16585200.
      View in: PubMed
    152. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006 Jul 15; 108(2):630-7. PMID: 16556893.
      View in: PubMed
    153. Koller C, Bekele BN, Zhou X, Park C, Estrov Z, O'Brien S, Keating M, Jilani I, Giles FJ, Kantarjian HM, Albitar M. Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood. 2006 Aug 1; 108(3):1001-6. PMID: 16551975.
      View in: PubMed
    154. Ravandi F, Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res. 2006 Jan 15; 12(2):340-4. PMID: 16428470.
      View in: PubMed
    155. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006 Jul 1; 108(1):45-51. PMID: 16403905.
      View in: PubMed
    156. Zhou Y, Garcia-Prieto C, Carney DA, Xu RH, Pelicano H, Kang Y, Yu W, Lou C, Kondo S, Liu J, Harris DM, Estrov Z, Keating MJ, Jin Z, Huang P. OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action. J Natl Cancer Inst. 2005 Dec 7; 97(23):1781-5. PMID: 16333034.
      View in: PubMed
    157. Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KW. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res. 2006 Jul; 30(7):801-11. PMID: 16332390.
      View in: PubMed
    158. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006 Mar 15; 107(6):2517-24. PMID: 16293603; PMCID: PMC1895741.
    159. Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 2006 Mar 15; 107(6):2501-6. PMID: 16291594.
      View in: PubMed
    160. Medeiros LJ, Estrov Z, Rassidakis GZ. Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma. Leuk Res. 2006 Apr; 30(4):497-501. PMID: 16203034.
      View in: PubMed
    161. Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F, Beran M. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer. 2005 Sep 15; 104(6):1230-6. PMID: 16078266.
      View in: PubMed
    162. Lev EI, Kleiman NS, Birnbaum Y, Harris D, Korbling M, Estrov Z. Circulating endothelial progenitor cells and coronary collaterals in patients with non-ST segment elevation myocardial infarction. J Vasc Res. 2005 Sep-Oct; 42(5):408-14. PMID: 16088214.
      View in: PubMed
    163. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer. 2005 Jul 11; 93(1):70-80. PMID: 15970928.
      View in: PubMed
    164. Faderl S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov Z. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Res. 2005 May-Jun; 25(3B):1841-50. PMID: 16158916.
      View in: PubMed
    165. Freireich EJ, Kurzrock R, Estrov Z. Metastasis--an alternative hypothesis. Cancer. 2005 Apr 15; 103(8):1537-9. PMID: 15739196.
      View in: PubMed
    166. Contractor R, Samudio IJ, Estrov Z, Harris D, McCubrey JA, Safe SH, Andreeff M, Konopleva M. A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. Cancer Res. 2005 Apr 1; 65(7):2890-8. PMID: 15805291.
      View in: PubMed
    167. Guikema JE, Fenton JA, de Boer C, Kleiverda K, Brink AA, Raap AK, Estrov Z, Schuuring E, Kluin PM. Complex biallelic IGH rearrangements in IgM-expressing Z-138 cell line: Involvement of downstream immunoglobulin class switch recombination. Genes Chromosomes Cancer. 2005 Feb; 42(2):164-9. PMID: 15543623.
      View in: PubMed
    168. Körbling M, Robinson S, Estrov Z, Champlin R, Shpall E. Umbilical cord blood-derived cells for tissue repair. Cytotherapy. 2005; 7(3):258-61. PMID: 16081352.
      View in: PubMed
    169. Zhang S, Wang D, Estrov Z, Raj S, Willerson JT, Yeh ET. Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. Circulation. 2004 Dec 21; 110(25):3803-7. PMID: 15596566.
      View in: PubMed
    170. Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, McQueen T, Monaco G, Munsell M, Belmont J, Kantarjian H, Sporn MB, Andreeff M. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res. 2004 Nov 1; 64(21):7927-35. PMID: 15520199.
      View in: PubMed
    171. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 1; 105(3):940-7. PMID: 15486072.
      View in: PubMed
    172. Verstovsek S, Estrov Z. Arsenic derivatives as therapeutic agents for hematologic malignancies. Leuk Res. 2004 Sep; 28(9):901-3. PMID: 15234564.
      View in: PubMed
    173. Bueso-Ramos CE, Ferrajoli A, Medeiros LJ, Keating MJ, Estrov Z. Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Hematology. 2004 Aug; 9(4):279-86. PMID: 15621735.
      View in: PubMed
    174. Hennessy B, Körbling M, Estrov Z. Circulating stem cells and tissue repair. Panminerva Med. 2004 Mar; 46(1):1-11. PMID: 15238877.
      View in: PubMed
    175. Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, Estrov Z, Smith TL, Nguyen MH, Aggarwal BB. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol. 2004 Feb; 35(2):246-53. PMID: 14991544.
      View in: PubMed
    176. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, Estrov Z, Mills GB, Andreeff M. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia. 2004 Feb; 18(2):267-75. PMID: 14628071.
      View in: PubMed
    177. Faderl S, Estrov Z. Hematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission. Leuk Lymphoma. 2004 Jan; 45(1):67-71. PMID: 15061199.
      View in: PubMed
    178. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004 Apr 15; 103(8):3175-84. PMID: 15070700.
      View in: PubMed
    179. Thompson MP, Aggarwal BB, Shishodia S, Estrov Z, Kurzrock R. Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1. Leukemia. 2003 Nov; 17(11):2196-201. PMID: 14523478.
      View in: PubMed
    180. Yeh ET, Zhang S, Wu HD, Körbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation. 2003 Oct 28; 108(17):2070-3. PMID: 14568894.
      View in: PubMed
    181. Laurent E, Mitchell DL, Estrov Z, Lowery M, Tucker SL, Talpaz M, Kurzrock R. Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair. Clin Cancer Res. 2003 Sep 1; 9(10 Pt 1):3722-30. PMID: 14506164.
      View in: PubMed
    182. Kørbling M, Estrov Z. Adult stem cells for tissue repair - a new therapeutic concept? N Engl J Med. 2003 Aug 7; 349(6):570-82. PMID: 12904523.
      View in: PubMed
    183. Körbling M, Estrov Z, Champlin R. Adult stem cells and tissue repair. Bone Marrow Transplant. 2003 Aug; 32 Suppl 1:S23-4. PMID: 12931235.
      View in: PubMed
    184. Grunberger T, Demin P, Rounova O, Sharfe N, Cimpean L, Dadi H, Freywald A, Estrov Z, Roifman CM. Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor. Blood. 2003 Dec 1; 102(12):4153-8. PMID: 12881315.
      View in: PubMed
    185. Faderl S, Estrov Z. Commentary: effect of flavonoids on normal and leukemic cells. Leuk Res. 2003 Jun; 27(6):471-3. PMID: 12648504.
      View in: PubMed
    186. Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ, Albitar M. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood. 2003 Sep 1; 102(5):1866-8. PMID: 12730116.
      View in: PubMed
    187. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Aggarwal BB. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003 Aug 1; 102(3):987-95. PMID: 12689943.
      View in: PubMed
    188. Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Estrov Z. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood. 2003 Jul 15; 102(2):630-7. PMID: 12663443.
      View in: PubMed
    189. Faderl S, Lotan R, Kantarjian HM, Harris D, Van Q, Estrov Z. N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res. 2003 Mar; 27(3):259-66. PMID: 12537979.
      View in: PubMed
    190. Ravandi F, Talpaz M, Estrov Z. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clin Cancer Res. 2003 Feb; 9(2):535-50. PMID: 12576416.
      View in: PubMed
    191. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles FJ. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):81-6. PMID: 12497210.
      View in: PubMed
    192. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood. 2002 Aug 15; 100(4):1215-9. PMID: 12149200.
      View in: PubMed
    193. Brouard M, Barrandon Y. Male cells in female recipients of hematopoietic-cell transplants. N Engl J Med. 2002 Jul 18; 347(3):218-20; author reply 218-20. PMID: 12124415.
      View in: PubMed
    194. Cheng K, Kurzrock R, Qiu X, Estrov Z, Ku S, Dulski KM, Wang JY, Talpaz M. Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells. Cancer. 2002 Jul 15; 95(2):440-50. PMID: 12124845.
      View in: PubMed
    195. Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S, Kantarjian HM. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res. 2002 Jul; 26(7):643-9. PMID: 12008081.
      View in: PubMed
    196. Faderl S, Thall PF, Kantarjian HM, Estrov Z. Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. Br J Haematol. 2002 Jun; 117(4):869-74. PMID: 12060122.
      View in: PubMed
    197. Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res. 2002 Jun; 26(6):551-9. PMID: 12007503.
      View in: PubMed
    198. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 2002 May 1; 99(9):3461-4. PMID: 11964319.
      View in: PubMed
    199. Körbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov Z. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med. 2002 Mar 7; 346(10):738-46. PMID: 11882729.
      View in: PubMed
    200. Ravandi F, Talpaz M, Kantarjian H, Estrov Z. Cellular signalling pathways: new targets in leukaemia therapy. Br J Haematol. 2002 Jan; 116(1):57-77. PMID: 11841398.
      View in: PubMed
    201. Hester J. RE: Therapeutic plasma exchange: a paired comparison of Fresenius AS104 vs. COBE Spectra. J Clin Apher. 2002; 17(1):49. PMID: 11948708.
      View in: PubMed
    202. Estrov Z, Huh YO, Ginsberg CF, Harris D, Van Q, Mirza NQ, Talpaz M, Korbling M. Ex vivo expansion of apheresis-derived peripheral blood hematopoietic progenitors. J Clin Apher. 2002; 17(1):7-16. PMID: 11948700.
      View in: PubMed
    203. Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, Sporn MB, Andreeff M. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood. 2002 Jan 1; 99(1):326-35. PMID: 11756188.
      View in: PubMed
    204. Faderl S, Estrov Z. Shift of immunoglobulin phenotypes in B-cell precursor cell lines. Leuk Res. 2002 Jan; 26(1):11-2. PMID: 11734298.
      View in: PubMed
    205. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res. 2001 Nov-Dec; 21(6A):3777-84. PMID: 11911247.
      View in: PubMed
    206. Kardinal C, Konkol B, Lin H, Eulitz M, Schmidt EK, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood. 2001 Sep 15; 98(6):1773-81. PMID: 11535511.
      View in: PubMed
    207. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff M. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001 Sep; 108(6):851-9. PMID: 11560954; PMCID: PMC200930.
    208. Torchilin VP, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol. 2001 Aug; 22(8):424-7. PMID: 11473830.
      View in: PubMed
    209. Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, Koller C, Estrov Z, Freireich E, Keating M, Albitar M. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 2001 Aug; 15(8):1165-70. PMID: 11480557.
      View in: PubMed
    210. Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar M. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001 Jun 1; 91(11):1964-72. PMID: 11391574.
      View in: PubMed
    211. Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S, Beran M, Kantarjian HM, Freireich EJ, Albitar M. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001 Apr; 7(4):795-9. PMID: 11309324.
      View in: PubMed
    212. Faderl S, Estrov Z. The clinical significance of caspase regulation in acute leukemia. Leuk Lymphoma. 2001 Feb; 40(5-6):471-81. PMID: 11426520.
      View in: PubMed
    213. Sarriera JE, Albitar M, Estrov Z, Gidel C, Aboul-Nasr R, Manshouri T, Kornblau S, Chang KS, Kantarjian H, Estey E. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia. 2001 Jan; 15(1):57-61. PMID: 11243400.
      View in: PubMed
    214. Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RB. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death. Cancer Res. 2001 Jan 1; 61(1):138-44. PMID: 11196151.
      View in: PubMed
    215. Stock W, Estrov Z. Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1289-305, viii-ix. PMID: 11147224.
      View in: PubMed
    216. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of minimal residual disease in leukemia. Int J Oncol. 2000 Dec; 17(6):1277-87. PMID: 11078816.
      View in: PubMed
    217. Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer. 2000 Nov 1; 89(9):1976-82. PMID: 11064355.
      View in: PubMed
    218. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E, Albitar M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000 Sep 15; 96(6):2240-5. PMID: 10979972.
      View in: PubMed
    219. Kardinal C, Konkol B, Schulz A, Posern G, Lin H, Adermann K, Eulitz M, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM. Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. FASEB J. 2000 Aug; 14(11):1529-38. PMID: 10928987.
      View in: PubMed
    220. Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, López-Berestein G, Andreeff M. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 2000 Jun 15; 95(12):3929-38. PMID: 10845930.
      View in: PubMed
    221. Mavligit GM, Estrov Z. CA 125: a clinically useful tumor marker in the management of colorectal carcinoma metastatic to the liver in patients with normal carcinoembryonic antigen. Am J Clin Oncol. 2000 Apr; 23(2):213-5. PMID: 10776987.
      View in: PubMed
    222. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000 Apr; 6(4):1401-9. PMID: 10778970.
      View in: PubMed
    223. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9. PMID: 10656456.
      View in: PubMed
    224. Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, Albitar M, Estrov Z. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000 Jan; 36(3-4):263-73. PMID: 10674898.
      View in: PubMed
    225. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999 Dec 1; 94(11):3717-21. PMID: 10572084.
      View in: PubMed
    226. Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M. A phase I study of recombinant interferon-beta in patients with advanced malignant disease. Clin Cancer Res. 1999 Dec; 5(12):3990-8. PMID: 10632330.
      View in: PubMed
    227. Faderl S, Thall PF, Kantarjian HM, Talpaz M, Harris D, Van Q, Beran M, Kornblau SM, Pierce S, Estrov Z. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999 Dec; 5(12):4041-7. PMID: 10632337.
      View in: PubMed
    228. Moravcová J, Nádvorníková S, Lukásová M, Klamová H. Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia. Blood. 1999 Nov 15; 94(10):3609-11. PMID: 10610116.
      View in: PubMed
    229. Faderl S, Kurzrock R, Estrov Z. Minimal residual disease in hematologic disorders. Arch Pathol Lab Med. 1999 Nov; 123(11):1030-4. PMID: 10539902.
      View in: PubMed
    230. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, Estey EH, Champlin RC, Kornblau SM, Reed JC, Zhao S. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999 Nov; 13(11):1881-92. PMID: 10557066.
      View in: PubMed
    231. Estrov Z, Manna SK, Harris D, Van Q, Estey EH, Kantarjian HM, Talpaz M, Aggarwal BB. Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood. 1999 Oct 15; 94(8):2844-53. PMID: 10515888.
      View in: PubMed
    232. Faderl S, Estrov Z, Kantarjian HM, Thomas D, Cortes J, Manshouri T, Chan CC, Hays KJ, Pierce S, Albitar M. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther. 1999 Sep; 5(3):159-63. PMID: 10641574.
      View in: PubMed
    233. Lion T. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making. Blood. 1999 Aug 15; 94(4):1486-8. PMID: 10484639.
      View in: PubMed
    234. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999 Aug 3; 131(3):207-19. PMID: 10428738.
      View in: PubMed
    235. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999 Jul 15; 341(3):164-72. PMID: 10403855.
      View in: PubMed
    236. Faderl S, Kantarjian HM, Manshouri T, Chan CY, Pierce S, Hays KJ, Cortes J, Thomas D, Estrov Z, Albitar M. The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. Clin Cancer Res. 1999 Jul; 5(7):1855-61. PMID: 10430092.
      View in: PubMed
    237. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999 Jul; 5(7):1758-66. PMID: 10430080.
      View in: PubMed
    238. Beaupre DM, Talpaz M, Marini FC, Cristiano RJ, Roth JA, Estrov Z, Albitar M, Freedman MH, Kurzrock R. Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. Cancer Res. 1999 Jun 15; 59(12):2971-80. PMID: 10383163.
      View in: PubMed
    239. Mavligit GM, Estrov Z, Ayala A. Carcinoma of the stomach metastatic to the liver that progressed after hepatic arterial infusion of cisplatin plus 5-floxuridine, and then dramatically regressed after chemoembolization based on positive chromogranin staining. Am J Clin Oncol. 1999 Jun; 22(3):320-2. PMID: 10362346.
      View in: PubMed
    240. Faderl S, Talpaz M, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood. 1999 May 1; 93(9):2755-9. PMID: 10216068.
      View in: PubMed
    241. Estrov Z, Freedman MH. Detection of residual disease in acute lymphoblastic leukemia of childhood. Leuk Lymphoma. 1999 Mar; 33(1-2):47-52. PMID: 10194120.
      View in: PubMed
    242. Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau SM, Dong J, Kliche KO, Jiang S, Snodgrass HR, Estey EH, Andreeff M. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood. 1999 Mar 1; 93(5):1668-76. PMID: 10029596.
      View in: PubMed
    243. Faderl S, Estrov Z. Detection of residual disease in childhood acute lymphoblastic leukemia. N Engl J Med. 1999 Jan 14; 340(2):152-3; author reply 153-4. PMID: 9917220.
      View in: PubMed
    244. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M. Apoptosis. Molecules and mechanisms. Adv Exp Med Biol. 1999; 457:217-36. PMID: 10500797.
      View in: PubMed
    245. Albitar M, Manshouri T, Kantarjian H, Keating M, Estrov Z, Faber J, Freireich EJ, Pierce S, Estey E. Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leuk Res. 1999 Jan; 23(1):63-9. PMID: 9933137.
      View in: PubMed
    246. Lee BN, Duvic M, Tang CK, Bueso-Ramos C, Estrov Z, Reuben JM. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol. 1999 Jan; 6(1):79-84. PMID: 9874668; PMCID: PMC95664.
    247. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998 Nov 1; 92(9):3090-7. PMID: 9787143.
      View in: PubMed
    248. Konopleva M, Estrov Z, Zhao S, Andreeff M, Mehta K. Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. J Immunol. 1998 Nov 1; 161(9):4702-8. PMID: 9794400.
      View in: PubMed
    249. Wright-Browne V, Schnee AM, Jenkins MA, Thall PF, Aggarwal BB, Talpaz M, Estrov Z. Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence. Leuk Lymphoma. 1998 Aug; 30(5-6):583-9. PMID: 9711920.
      View in: PubMed
    250. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998 Jul; 4(7):1661-72. PMID: 9676840.
      View in: PubMed
    251. Ferrajoli A, Talpaz M, Kurzrock R, Harris D, Van Q, Estey EH, Estrov Z. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. Leuk Lymphoma. 1998 Jul; 30(3-4):279-92. PMID: 9713960.
      View in: PubMed
    252. Faderl S, Estrov Z. The clinical significance of detection of residual disease in childhood ALL. Crit Rev Oncol Hematol. 1998 Jun; 28(1):31-55. PMID: 9715769.
      View in: PubMed
    253. Faderl S, Estrov Z. Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevance. Cytokines Cell Mol Ther. 1998 Jun; 4(2):73-85. PMID: 9681246.
      View in: PubMed
    254. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998 Jun 1; 91(11):3995-4019. PMID: 9596644.
      View in: PubMed
    255. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 1998 Apr; 16(4):1526-31. PMID: 9552062.
      View in: PubMed
    256. Estrov Z, Talpaz M, Ku S, Harris D, Van Q, Beran M, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. Leuk Res. 1998 Apr; 22(4):341-53. PMID: 9669839.
      View in: PubMed
    257. Liu J, Hadjokas N, Mosley B, Estrov Z, Spence MJ, Vestal RE. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine. 1998 Apr; 10(4):295-302. PMID: 9617575.
      View in: PubMed
    258. Dhingra K, Sahin A, Emami K, Hortobagyi GN, Estrov Z. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat. 1998 Mar; 48(2):165-74. PMID: 9596488.
      View in: PubMed
    259. Kurzrock R, Estrov Z, Ku S, Leonard M, Talpaz M. Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines. J Lab Clin Med. 1998 Mar; 131(3):261-8. PMID: 9523851.
      View in: PubMed
    260. Kurzrock R, Talpaz M, Beran M, Harris D, Estrov Z. DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia. Leukemia. 1998 Feb; 12(2):242-6. PMID: 9519789.
      View in: PubMed
    261. Peleg S, Qiu H, Reddy S, Harris D, Van Q, Estey EH, Talpaz M, Estrov Z. 1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production. J Clin Invest. 1997 Oct 1; 100(7):1716-24. PMID: 9312169.
      View in: PubMed
    262. Wetzler M, Kurzrock R, Estrov Z, Barone S, Estey E, Talpaz M. Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4. Leuk Res. 1997 Jun; 21(6):519-27. PMID: 9279363.
      View in: PubMed
    263. Wright-Browne V, McClain KL, Talpaz M, Ordonez N, Estrov Z. Physiology and pathophysiology of dendritic cells. Hum Pathol. 1997 May; 28(5):563-79. PMID: 9158705.
      View in: PubMed
    264. Estrov Z, Talpaz M. Role of interleukin-1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death. Leuk Lymphoma. 1997 Feb; 24(5-6):379-91. PMID: 9086432.
      View in: PubMed
    265. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med. 1997 Jan 30; 336(5):317-23. PMID: 9011783.
      View in: PubMed
    266. McClain K, Estrov Z, Raju U, Kelley PK, Aggarwal BB. Epstein-Barr Virus EBNA-2 gene expression enhances lymphotoxin production by B lymphocytes. Methods. 1997 Jan; 11(1):83-7. PMID: 8990093.
      View in: PubMed
    267. Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff M. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood. 1996 Nov 15; 88(10):3987-97. PMID: 8916965.
      View in: PubMed
    268. Lapidot T, Grunberger T, Vormoor J, Estrov Z, Kollet O, Bunin N, Zaizov R, Williams DE, Freedman MH. Identification of human juvenile chronic myelogenous leukemia stem cells capable of initiating the disease in primary and secondary SCID mice. Blood. 1996 Oct 1; 88(7):2655-64. PMID: 8839860.
      View in: PubMed
    269. Estrov Z, Talpaz M, Ku S, Harris D, LaPushin R, Koller CA, Hirsh-Ginsberg C, Huh Y, Yee G, Kurzrock R. Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF. Leukemia. 1996 Sep; 10(9):1534-43. PMID: 8751477.
      View in: PubMed
    270. Kellokumpu-Lehtinen P, Talpaz M, Harris D, Van Q, Kurzrock R, Estrov Z. Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer. 1996 May 16; 66(4):515-9. PMID: 8635867.
      View in: PubMed
    271. Sarris AH, Talpaz M, Deisseroth AB, Estrov Z. Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors. Leukemia. 1996 May; 10(5):757-65. PMID: 8656668.
      View in: PubMed
    272. Estrov Z, Talpaz M, Zipf TF, Kantarjian HM, Ku S, Ouspenskaia MV, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol. 1996 Mar; 166(3):618-30. PMID: 8600166.
      View in: PubMed
    273. Estrov Z, Talpaz M. Role of interleukin-1 beta converting enzyme (ICE) in leukemia. Cytokines Mol Ther. 1996 Mar; 2(1):1-11. PMID: 9384684.
      View in: PubMed
    274. Roberts WM, Estrov Z, Kitchingman GR, Zipf TF. Detection of minimal residual disease in all: biology, methods, and applications. Cancer Treat Res. 1996; 84:149-66. PMID: 8724630.
      View in: PubMed
    275. Roberts WM, Estrov Z, Kitchingman GR, Zipf TF. The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences. Leuk Lymphoma. 1996 Jan; 20(3-4):181-97. PMID: 8624456.
      View in: PubMed
    276. Estrov Z, Black RA, Sleath PR, Harris D, Van Q, LaPushin R, Estey EH, Talpaz M. Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood. 1995 Dec 15; 86(12):4594-602. PMID: 8541550.
      View in: PubMed
    277. Estrov Z, Samal B, Lapushin R, Kellokumpu-Lehtinen P, Sahin AA, Kurzrock R, Talpaz M, Aggarwal BB. Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. J Interferon Cytokine Res. 1995 Oct; 15(10):905-13. PMID: 8564713.
      View in: PubMed
    278. Kurzrock R, Wetzler M, Estrov Z, Talpaz M. Interleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth regulatory factors in leukemias. Cytokines Mol Ther. 1995 Sep; 1(3):177-84. PMID: 9384674.
      View in: PubMed
    279. Estrov Z, Talpaz M, Estey EH, Strassmann G. Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation. Exp Hematol. 1995 Sep; 23(10):1080-7. PMID: 7544738.
      View in: PubMed
    280. Roberts WM, Estrov Z, Zipf TF. Detection of minimal residual disease in acute lymphoblastic leukemia. Blood. 1995 Aug 1; 86(3):1237-9. PMID: 7620179.
      View in: PubMed
    281. Estrov Z, Kurzrock R, Talpaz M. Cytokines and their antagonists in myeloid disorders. Semin Hematol. 1995 Jul; 32(3):220-31. PMID: 7570065.
      View in: PubMed
    282. Estrov Z, Talpaz M, Mavligit G, Pazdur R, Harris D, Greenberg SM, Kurzrock R. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med. 1995 Jun; 98(6):551-8. PMID: 7539977.
      View in: PubMed
    283. Attias D, Grunberger T, Vanek W, Estrov Z, Cohen A, Lau R, Freedman MH. B-lineage lymphoid blast crisis in juvenile chronic myelogenous leukemia: II. Interleukin-1-mediated autocrine growth regulation of the lymphoblasts. Leukemia. 1995 May; 9(5):884-8. PMID: 7769852.
      View in: PubMed
    284. Roberts WM, Zipf TF, Kitchingman GR, Tubergen DG, Estrov Z. Monitoring residual disease in acute lymphoblastic leukemia: therapeutic implications. Cytokines Mol Ther. 1995 Mar; 1(1):65-9. PMID: 9384665.
      View in: PubMed
    285. Ouspenskaia MV, Johnston DA, Roberts WM, Estrov Z, Zipf TF. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia. 1995 Feb; 9(2):321-8. PMID: 7869771.
      View in: PubMed
    286. Wetzler M, Kurzrock R, Estrov Z, Estey E, Talpaz M. Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. Leuk Res. 1995 Jan; 19(1):23-34. PMID: 7837815.
      View in: PubMed
    287. Estrov Z, Kurzrock R, Talpaz M. Interleukin-1 and its inhibitors: implications for disease biology and therapy. Cancer Treat Res. 1995; 80:51-82. PMID: 8821574.
      View in: PubMed
    288. Przepiorka D, Madden T, Ippoliti C, Estrov Z, Dimopoulos M. Dosing of thioTEPA for myeloablative therapy. Cancer Chemother Pharmacol. 1995; 37(1-2):155-60. PMID: 7497586.
      View in: PubMed
    289. Drach D, Estrov Z, Zhao S, Drach J, Cork A, Collins D, Kantarjian H, Andreeff M. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia. Leuk Lymphoma. 1994 Dec; 16(1-2):79-88. PMID: 7535143.
      View in: PubMed
    290. Wetzler M, Kurzrock R, Estrov Z, Kantarjian H, Gisslinger H, Underbrink MP, Talpaz M. Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood. 1994 Nov 1; 84(9):3142-7. PMID: 7949186.
      View in: PubMed
    291. Ferrajoli A, Talpaz M, Ordonez NG, Stanley ER, Hirsch-Ginsberg C, Zipf TF, Wetzler M, Kurzrock R, Estrov Z. Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors. Stem Cells. 1994 Nov; 12(6):638-49. PMID: 7533582.
      View in: PubMed
    292. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest. 1994 Oct; 94(4):1383-9. PMID: 7929813.
      View in: PubMed
    293. Ferrajoli A, Talpaz M, Zipf TF, Hirsch-Ginsberg C, Estey E, Wolpe SD, Estrov Z. Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha. Leukemia. 1994 May; 8(5):798-805. PMID: 8182937.
      View in: PubMed
    294. Estrov Z, Ouspenskaia MV, Zipf TF, Tubergen DG, Roberts WM. Minimal residual leukaemia. Lancet. 1994 Apr 2; 343(8901):858-9. PMID: 7908106.
      View in: PubMed
    295. Wetzler M, Estrov Z, Talpaz M, Kim KJ, Alphonso M, Srinivasan R, Kurzrock R. Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha. Cancer Res. 1994 Apr 1; 54(7):1837-42. PMID: 8137298.
      View in: PubMed
    296. Estrov Z, Ouspenskaia MV, Felix EA, McClain KL, Lee MS, Harris D, Pinkel DP, Zipf TF. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. Leukemia. 1994 Jan; 8(1):46-52. PMID: 8289497.
      View in: PubMed
    297. Ferrajoli A, Zipf TF, Talpaz M, Felix EA, Estrov Z. Growth factors controlling interleukin-4 action on hematopoietic progenitors. Ann Hematol. 1993 Dec; 67(6):277-84. PMID: 7506581.
      View in: PubMed
    298. Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R. Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. J Intern Med. 1993 Oct; 234(4):417-20. PMID: 7691980.
      View in: PubMed
    299. McClain K, Estrov Z, Chen H, Mahoney DH. Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies. Br J Haematol. 1993 Sep; 85(1):57-62. PMID: 8251410.
      View in: PubMed
    300. Estrov Z, Re GG, Zipf TF. Immature and differentiated neoplastic populations in acute lymphoid leukemia of childhood: biological and clinical implications. Leuk Lymphoma. 1993 Sep; 11(1-2):1-7. PMID: 8220141.
      View in: PubMed
    301. Estrov Z, Kurzrock R, Talpaz M. Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. Leuk Lymphoma. 1993 Aug; 10(6):407-18. PMID: 8401177.
      View in: PubMed
    302. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993 Aug 1; 82(3):691-703. PMID: 8338938.
      View in: PubMed
    303. Estrov Z, Talpaz M, Kantarjian HM, Zipf TF, McClain KL, Kurzrock R. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction. Cancer Res. 1993 Jul 15; 53(14):3289-93. PMID: 8324740.
      View in: PubMed
    304. Estrov Z. Interruption of autocrine and paracrine growth-stimulatory mechanisms: a new therapeutic strategy for chronic myelogenous leukemia. Semin Hematol. 1993 Jul; 30(3 Suppl 3):35-6. PMID: 7694373.
      View in: PubMed
    305. Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB. Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med. 1993 Mar 1; 177(3):763-74. PMID: 8382256.
      View in: PubMed
    306. Ferrajoli A, Talpaz M, Kurzrock R, Estrov Z. Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. Stem Cells. 1993 Mar; 11(2):112-9. PMID: 8384506.
      View in: PubMed
    307. Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia. 1993 Feb; 7(2):214-20. PMID: 8426475.
      View in: PubMed
    308. Kurzrock R, Kantarjian H, Wetzler M, Estrov Z, Estey E, Troutman-Worden K, Gutterman JU, Talpaz M. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol. 1993 Jan; 21(1):80-5. PMID: 8417962.
      View in: PubMed
    309. Zadik Z, Estrov Z, Karov Y, Hahn T, Barak Y. The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission--a preliminary report. J Pediatr Endocrinol. 1993 Jan-Mar; 6(1):79-83. PMID: 8374694.
      View in: PubMed
    310. Wetzler M, Talpaz M, Estrov Z, Kurzrock R. CML: mechanisms of disease initiation and progression. Leuk Lymphoma. 1993; 11 Suppl 1:47-50. PMID: 8251916.
      View in: PubMed
    311. Estrov Z, Talpaz M, Wetzler M, Kurzrock R. The modulatory hematopoietic activities of leukemia inhibitory factor. Leuk Lymphoma. 1992 Sep; 8(1-2):1-7. PMID: 1493463.
      View in: PubMed
    312. Estrov Z, Park CH, Reading CL, Estey EH, Talpaz M, Kurzrock R, Deisseroth AB, Gutterman JU. The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors. Exp Hematol. 1992 Aug; 20(7):886-90. PMID: 1628706.
      View in: PubMed
    313. Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Exp Hematol. 1992 Jun; 20(5):558-64. PMID: 1587302.
      View in: PubMed
    314. Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D, Blake M, Gutterman JU, Talpaz M. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood. 1992 Apr 15; 79(8):1938-45. PMID: 1373331.
      View in: PubMed
    315. Freedman MH, Cohen A, Grunberger T, Bunin N, Luddy RE, Saunders EF, Shahidi N, Lau A, Estrov Z. Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia. Br J Haematol. 1992 Jan; 80(1):40-8. PMID: 1311195.
      View in: PubMed
    316. Estrov Z, Kurzrock R, Talpaz M, Blake M, Gutterman JU. Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. Ann Hematol. 1991 Dec; 63(6):297-301. PMID: 1756190.
      View in: PubMed
    317. Kurzrock R, Talpaz M, Estey E, O'Brien S, Estrov Z, Gutterman JU. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia. 1991 Nov; 5(11):985-90. PMID: 1961041.
      View in: PubMed
    318. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood. 1991 Sep 15; 78(6):1476-84. PMID: 1715791.
      View in: PubMed
    319. Re GG, Estrov Z, Antoun GR, Felix EA, Pinkel DP, Zipf TF. Differentiation in B-precursor acute lymphoblastic leukemia cell populations with CD34-positive subpopulations. Blood. 1991 Aug 1; 78(3):575-80. PMID: 1713508.
      View in: PubMed
    320. Kurzrock R, Estrov Z, Wetzler M, Gutterman JU, Talpaz M. LIF: not just a leukemia inhibitory factor. Endocr Rev. 1991 Aug; 12(3):208-17. PMID: 1935819.
      View in: PubMed
    321. Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol. 1991 Jul; 9(7):1241-50. PMID: 2045865.
      View in: PubMed
    322. Estrov Z, Freedman MH. Acute lymphoblastic leukemia blast cells do not inhibit bone marrow hematopoietic progenitor colony formation. Exp Hematol. 1991 Mar; 19(3):221-5. PMID: 1995313.
      View in: PubMed
    323. Estrov Z, Meir R, Barak Y, Zaizov R, Zadik Z. Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts. J Clin Oncol. 1991 Mar; 9(3):394-9. PMID: 1999709.
      View in: PubMed
    324. Estrov Z, Talpaz M, Chou TC, Kurzrock R, Blake M, Gutterman JU. Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia. Leukemia. 1991 Feb; 5(2):101-7. PMID: 2020193.
      View in: PubMed
    325. Kurzrock R, Estrov Z, Talpaz M, Gutterman JU. Cytokines in tumor therapy. Interleukin-3. Am J Clin Oncol. 1991; 14 Suppl 1:S45-50. PMID: 2048564.
      View in: PubMed
    326. Estrov Z, Resnitzky P. [Hematopoietic growth factors and their clinical application]. Harefuah. 1990 Jan 15; 118(2):111-7. PMID: 1690162.
      View in: PubMed
    327. Cohen A, Madrid-Marina V, Estrov Z, Freedman MH, Lingwood CA, Dosch HM. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol. 1990; 2(1):1-8. PMID: 1965141.
      View in: PubMed
    328. Freedman MH, Estrov Z. Congenital amegakaryocytic thrombocytopenia: an intrinsic hematopoietic stem cell defect. Am J Pediatr Hematol Oncol. 1990; 12(2):225-30. PMID: 2378417.
      View in: PubMed
    329. Estrov Z, Freedman MH. [Recent advances in juvenile chronic myelogenous leukemia]. Harefuah. 1989 May 10; 116(10):538-41. PMID: 2676769.
      View in: PubMed
    330. Halperin DS, Estrov Z, Freedman MH. Diamond-Blackfan anemia: promotion of marrow erythropoiesis in vitro by recombinant interleukin-3. Blood. 1989 Apr; 73(5):1168-74. PMID: 2649168.
      View in: PubMed
    331. Estrov Z, Berrebi A, Kusminsky G, Resnitzky P. Circulating mononuclear cells from pure red cell aplasia of chronic lymphocytic leukemia suppress in vitro erythropoiesis. Acta Haematol. 1989; 81(4):213-6. PMID: 2502895.
      View in: PubMed
    332. Estrov Z, Freedman MH. Growth requirements for human acute lymphoblastic leukemia cells: refinement of a clonogenic assay. Cancer Res. 1988 Oct 15; 48(20):5901-7. PMID: 3048651.
      View in: PubMed
    333. Estrov Z, Halperin DS, Coceani F, Freedman MH. Modulation of human marrow haematopoiesis by leucotrienes in vitro. Br J Haematol. 1988 Jul; 69(3):321-7. PMID: 2841965.
      View in: PubMed
    334. Estrov Z, Cohen A, Gelfand EW, Freedman MH. Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity. Am J Pediatr Hematol Oncol. 1988; 10(4):288-91. PMID: 3239704.
      View in: PubMed
    335. Freedman MH, Estrov Z, Chan HS. Juvenile chronic myelogenous leukemia. Am J Pediatr Hematol Oncol. 1988; 10(3):261-7. PMID: 3052147.
      View in: PubMed
    336. Estrov Z, Cohen A, Gelfand EW, Freedman MH. In vitro cytotoxicity of deferoxamine on human marrow haematopoietic progenitors. Toxicol In Vitro. 1988; 2(2):131-4. PMID: 20702348.
      View in: PubMed
    337. Chan HS, Estrov Z, Weitzman SS, Freedman MH. The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. J Clin Oncol. 1987 Dec; 5(12):1960-7. PMID: 2445935.
      View in: PubMed
    338. Estrov Z, Dubé ID, Chan HS, Freedman MH. Residual juvenile chronic myelogenous leukemia cells detected in peripheral blood during clinical remission. Blood. 1987 Nov; 70(5):1466-9. PMID: 3478101.
      View in: PubMed
    339. Kaplinsky C, Estrov Z, Freedman MH, Gelfand EW, Cohen A. Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells. Leukemia. 1987 May; 1(5):437-41. PMID: 3312841.
      View in: PubMed
    340. Estrov Z, Roifman C, Mills G, Grunberger T, Gelfand EW, Freedman MH. The regulatory role of interleukin 2-responsive T lymphocytes on human marrow granulopoiesis. Blood. 1987 Apr; 69(4):1161-6. PMID: 3103713.
      View in: PubMed
    341. Freedman MH, Estrov Z. Juvenile chronic myelogenous leukaemia and histiocytosis syndromes in children. Lancet. 1987 Mar 28; 1(8535):754. PMID: 2882175.
      View in: PubMed
    342. Estrov Z, Tawa A, Wang XH, Dubé ID, Sulh H, Cohen A, Gelfand EW, Freedman MH. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood. 1987 Mar; 69(3):757-61. PMID: 3493042.
      View in: PubMed
    343. Estrov Z, Lau AS, Williams BR, Freedman MH. Recombinant human interferon alpha-2 and juvenile chronic myelogenous leukemia: cell receptor binding, enzymatic induction, and growth suppression in vitro. Exp Hematol. 1987 Feb; 15(2):127-32. PMID: 3102273.
      View in: PubMed
    344. Estrov Z, Zimmerman B, Grunberger T, Chao J, Teshima IE, Chan HS, Freedman MH. Characterization of malignant peripheral blood cells of juvenile chronic myelogenous leukemia. Cancer Res. 1986 Dec; 46(12 Pt 1):6456-61. PMID: 3465439.
      View in: PubMed
    345. Nussinson E, Lahav M, Berebi A, Estrov Z, Zur S, Resnitzky P. Secretory piece and IgA deficiency in a patient with Waldenstrom's macroglobulinemia. Am J Gastroenterol. 1986 Oct; 81(10):995-8. PMID: 3094364.
      View in: PubMed
    346. Estrov Z, Grunberger T, Freedman MH. Clinical utility of marrow cell tissue cultures in acute leukemia of childhood. Am J Hematol. 1986 Sep; 23(1):51-8. PMID: 3461711.
      View in: PubMed
    347. Estrov Z, Grunberger T, Dubé ID, Wang YP, Freedman MH. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N Engl J Med. 1986 Aug 28; 315(9):538-42. PMID: 3488505.
      View in: PubMed
    348. Estrov Z, Roifman C, Wang YP, Grunberger T, Gelfand EW, Freedman MH. The regulatory role of interleukin 2-responsive T lymphocytes on early and mature erythroid progenitor proliferation. Blood. 1986 Jun; 67(6):1607-10. PMID: 3486684.
      View in: PubMed
    349. Estrov Z, Grunberger T, Chan HS, Freedman MH. Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures. Blood. 1986 May; 67(5):1382-7. PMID: 3486010.
      View in: PubMed
    350. Kaplinsky C, Yeger H, Estrov Z, Barankiewicz J, Pawlin G, Freedman MH, Cohen A. Selective protection of tubercidin toxicity by nitrobenzyl thioinosine in normal tissues but not in human neuroblastoma cells. Cancer Chemother Pharmacol. 1986; 17(3):264-8. PMID: 3742712.
      View in: PubMed
    351. Freedman MH, Estrov Z, Williams BR, Gelfand EW. Clinical and in vitro antiproliferative properties of recombinant DNA-derived human interferon-alpha 2. Am J Pediatr Hematol Oncol. 1986; 8(3):178-82. PMID: 3766908.
      View in: PubMed
    352. Bernstein A, Dick JE, Huszar D, Robson I, Rossant J, Magli C, Estrov Z, Freedman M, Phillips RA. Genetic engineering of mouse and human stem cells. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 2:1083-91. PMID: 3472753.
      View in: PubMed
    353. Kaplinsky C, Estrov Z, Freedman MH, Cohen A. Induction of differentiation in HL-60 promyelocytic cells: a comparative study in two sublines. Blood Cells. 1986; 11(3):459-68. PMID: 3461855.
      View in: PubMed
    354. Freedman MH, Fish E, Estrov Z, Grunberger T, Williams BR. Growth inhibitory effect of gene-cloned interferons on human myeloblast colonies. Exp Hematol. 1985 Oct; 13(9):932-6. PMID: 3862600.
      View in: PubMed
    355. Arcavi L, Estrov Z, Caspi A, Resnitzky P. [Severe side-effects of captopril]. Harefuah. 1985 May 1; 108(9):439-41. PMID: 3896985.
      View in: PubMed
    356. Resnitzky P, Estrov Z, Haran-Ghera N. High incidence of acute myeloid leukemia in SJL/J mice after X-irradiation and corticosteroids. Leuk Res. 1985; 9(12):1519-28. PMID: 3866124.
      View in: PubMed
    357. Wishnitzer R, Estrov Z, Caspi A, Eliraz A. [Pneumonitis due to amiodarone]. Harefuah. 1984 Sep; 107(5-6):131-3. PMID: 6510818.
      View in: PubMed
    358. Estrov Z, Resnitzky P, Shenker Y, Berrebi A, Hurwitz N. Candidemia and sternal Candida albicans osteomyelitis in a patient with chronic lymphatic leukemia. Isr J Med Sci. 1984 Aug; 20(8):711-4. PMID: 6469595.
      View in: PubMed
    359. Estrov Z, Bruck R, Shtalrid M, Berrebi A, Resnitzky P. Histiocytic hemophagocytosis in Q fever. Arch Pathol Lab Med. 1984 Jan; 108(1):7. PMID: 6546341.
      View in: PubMed
    360. Coslovsky R, Bruck R, Estrov Z. Hypo-osmolal syndrome due to prolonged nausea. Arch Intern Med. 1984 Jan; 144(1):191-2. PMID: 6691759.
      View in: PubMed
    361. Estrov Z, Resnitzky P. Enhancement of hemopoietic stem cell proliferation by prostaglandin inhibitory drugs. Exp Hematol. 1983 Oct; 11(9):802-9. PMID: 6139289.
      View in: PubMed
    362. Berrebi A, Estrov Z, Chemke J. Chronic myeloid leukemia following radiotherapy for breast cancer. Isr J Med Sci. 1983 Jul; 19(7):653-4. PMID: 6576990.
      View in: PubMed
    363. Bruck R, Estrov Z, Resnitzky P, Bar-Khayim Y. Recurrent anuria in severe hypercapnic acidosis. Isr J Med Sci. 1983 Jul; 19(7):649-50. PMID: 6885351.
      View in: PubMed
    364. Estrov Z, Berrebi A, Nussinson E, Kohn D. [Sinus histiocytosis with massive lymphadenopathy]. Harefuah. 1983 May 1; 104(9):387-9. PMID: 6674048.
      View in: PubMed
    365. Estrov Z, Berrebi A, Hazani E, Resnitzky P. Pleural effusion and ascites as presenting signs of IgA myeloma. Haematologica. 1983 Jan-Feb; 68(1):104-9. PMID: 6404700.
      View in: PubMed
    366. Shenker Y, Estrov Z, Nussinson E, Landau Z, Resnitzky P. [Schistosomiasis mansoni infestation treated with oxamnaquine]. Harefuah. 1982 Nov 1; 103(9):199-200. PMID: 7169187.
      View in: PubMed
    367. Naparstek Y, Ben-Chetrit E, Okon E, Estrov Z, Eliakim M. Angioimmunoblastic lymphadenopathy in a patient with allergy to insulin: a case report. Cancer. 1981 Feb 1; 47(3):545-7. PMID: 7013961.
      View in: PubMed
    368. Berrebi A, Estrov Z. Twenty years follow-up in a patient with multiple myeloma. Acta Haematol. 1981; 66(4):269-70. PMID: 6800195.
      View in: PubMed
    369. Estrov Z, Kohn D, Sofer O, Schonfeld S. [Acute renal failure as a result of intravenous cholangiography (meglumine iodipamide)]. Harefuah. 1978 Feb; 94(3-4):133-4. PMID: 658793.
      View in: PubMed
    370. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer.
    371. Hematopoietec growth factors and cytokines. Journal of Clinical Ligand Assay. 23:169-180.
    372. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. American Journal of Hematology. 91:E478-E479.
    373. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica. 102:79-84.
    374. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia. The Lancet Haematology.
    375. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine.
    376. Ocular extramedullary myeloid leukaemia. British Journal of Haematology.
    377. Interruption of endogenous growth regulatory networks. FORUM - Trends in Experimental and Clinical Medicine. 3:306-318.
    378. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia. 16:163-168.
    379. Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. American Journal of Hematology. 90:1091-1092.
    380. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leukemia and Lymphoma. 1-5.
    381. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. Journal of Experimental Medicine. 213:1723-1740.
    382. Relapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemia. Journal of Clinical Oncology. 34:e57-e60.
    383. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 101:e254-e258.
    384. In vitro cytotoxicity of deferoxamine on human marrow haematopoietic progenitors. Toxicology in Vitro. 2:131-134.
    385. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology.
    386. Targeting signal transducer and activator of transcription (STAT) for anticancer therapy. 299-321.
    387. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. Oncogene.
    388. At high levels, constitutively activated STAT3 induces apoptosis of chronic lymphocytic leukemia cells. Journal of Immunology. 196:4400-4409.
    389. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - Single center experience. Leukemia and Lymphoma. 57:237-239.
    390. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. British Journal of Haematology. 171:281-284.
    391. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 7:14172-14187.
    392. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia.
    393. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    394. Aberrant LPL expression, driven by STAT3, Mediates free fatty acid metabolism in cll cells. Molecular Cancer Research. 13:944-953.
    395. Metabolism pathways in chronic lymphocytic leukemia. Leukemia and Lymphoma. 57:758-765.
    396. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy. Leukemia and Lymphoma. 56:1643-1650.
    397. Signal transduction in rheumatology-from bench to bedside. Current Rheumatology Reviews. 7:273.
    398. Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leukemia and Lymphoma. 56:1392-1397.
    399. Interruption of autocrine/paracrine growth factor stimulatory mechanisms. International Journal of Pediatric Hematology/Oncology. 1:253-258.
    400. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Oncology. 16:1547-1555.
    401. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer genetics. 208:571-574.
    402. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 120:3494-3501.
    403. Response. Blood. 116:500.
    404. Myeloid neoplasms after breast cancer. Leukemia and Lymphoma. 56:1012-1019.
    405. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 127:1269-1275.
    406. Growth factor inhibitory molecules. Interferons and Cytokines. 22-25.
    407. Hemophagocytic lymphohistiocytosis in adults. BBA Clinical. 7:36-40.
    408. Meir Wetzler, MD. Cancer.
    409. β2-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 122:565-573.
    410. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. American Journal of Hematology. 91:354-355.
    411. Potential therapeutic utility of ICE inhibitors in leukemia. Drug News and Perspectives. 9:5-12.
    412. Describing a transcription factor dependent regulation of the micro RNA transcriptome. Journal of Visualized Experiments. 2016.
    413. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed. Leukemia and Lymphoma.
    414. Inihibition of PI3K by LY294002 promotes apoptosis and dephosphorylates bad in myeloid leukemias. Blood. 96.
    415. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 121:3612-3621.
    416. TP53 mutations in newly diagnosed acute myeloid leukemia. Cancer. 122:3484-3491.
    417. Residual disease in acute lymphoblastic leukemia of childhood. International Journal of Pediatric Hematology/Oncology. 5:251-266.
    418. Philadelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation. American Journal of Hematology.
    419. Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia. Journal of Immunology. 197:2522-2531.
    ESTROV's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description